Recovering scientist turned early stage VC A biotech optimist fighting gravity

Chinese Biopharma: The Next Five Years
October 2, 2026

By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are an avid consumer of biopharma news, you are probably all too familiar with the graphs that plot the growth

Leave a comment

Get with the Program!
September 10, 2026

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC If you ask anyone who has run a drug development program what factors determine whether it succeeds or not, the answer is rarely

Leave a comment

Make US INDs Great Again
August 17, 2026

By Alex Harding, Entrepreneur-in-Residence at Atlas Venture, as part of the From The Trenches feature of LifeSciVC What will and will not work to regain US strength in phase 1 clinical trials “I don’t know anyone who runs their phase

Leave a comment

Evolving Drug Discovery: AI, Infrastructure, and the Speed of Learning
July 28, 2026

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC The Japanese Zen term shoshin means “beginner’s mind”. It’s the discipline of approaching familiar territory with fresh eyes and openness to see what

Leave a comment

The Plus-1 in “The Room Where It Happens”: A Survival Guide for Board Observers
July 17, 2026

By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Before attending my first board meeting, I fondly remember imagining a board as the “Room Where It Happens,” yearningly described by Aaron

Leave a comment

Two Roads Diverged
June 30, 2026

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC In most companies I am fortunate to be a part of, there is a strong relationship between investors and operators. But every so

Leave a comment

Biotech’s Most Effective Medicine: No FDA Approval Required
June 8, 2026

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC We work in a serious business — endeavoring to make people’s lives better and, in some cases, literally saving lives. It is a

Leave a comment

Patient-first, America-first: The Case For Global Collaboration
June 2, 2026

The rise of China in the global biopharma ecosystem has led to fear and hysteria in some corners of our ecosystem.  Apparently there have been too many deals with Chinese players by both venture investors and Big Pharma. US biotech

Leave a comment

Year One as CEO: What Leadership Actually Feels Like
April 28, 2026

By Abbas Kazimi, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC There’s a version of leadership that presents cleanly from the outside: the presence in the room, the confidence behind decisions, the sense of

Leave a comment

Stay Humble: Life Sciences as a Small Slice of an Increasingly Big Venture Pie
April 23, 2026

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “Travel makes one modest. You see what a tiny place you occupy in the world.” — Gustave Flaubert Life sciences in April 2026

Leave a comment

Do One Thing Every Day That Scares You
April 7, 2026

By Linda Bain, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “Do one thing every day that scares you” – Eleanor Roosevelt I remember the first time I consciously stepped out of my

Leave a comment

How (and why) do you measure a year in the life? A Practical Guide to Defining Clinical Unmet Need
April 2, 2026

By Julia Pian, Senior Associate at Atlas Venture, as part of the From The Trenches features of LifeSciVC As Jonathan Larson beautifully explores in “Seasons of Love” from Rent, it’s almost impossible to find the right variables to capture life

Leave a comment



Verified by ExactMetrics